...
首页> 外文期刊>British Journal of Cancer >Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models
【24h】

Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models

机译:鞘磷脂-胆固醇脂质体在鼠和人肿瘤模型中显着增强长春新碱的药代动力学和治疗特性

获取原文

摘要

This study reports on the development of a liposomal formulation of vincristine with significantly enhanced stability and biological properties. The in vitro and in vivo pharmacokinetic, tumour delivery and efficacy properties of liposomal vincristine formulations based on sphingomyelin (SM) and cholesterol were compared with liposomes composed of distearoylphosphatidylcholine (DSPC) and cholesterol. SM/cholesterol liposomes had significantly greater in vitro stability than did similar DSPC/cholesterol liposomes. SM/cholesterol liposomes also had significantly improved biological properties compared with DSPC/cholesterol. Specifically, SM/cholesterol liposomes administered intravenously retained 25% of the entrapped vincristine after 72 h in the circulation, compared with 5% retention in DSPC/cholesterol liposomes. The improved retention properties of SM/cholesterol liposomes resulted in plasma vincristine levels 7-fold higher than in DSPC/cholesterol liposomes. The improved circulation lifetime of vincristine in SM/cholesterol liposomes correlated with increased vincristine accumulation in peritoneal ascitic murine P388 tumours and in subcutaneous solid A431 human xenograft tumours. Increased vincristine delivery to tumours was also accompanied by increased anti-tumour efficacy. Treatment with SM/cholesterol liposomal formulations of vincristine resulted in greater than 50% cures in mice bearing ascitic P388 tumours, an activity that could not be achieved with the DSPC/cholesterol formulation. Similarly, treatment of mice with severe combined immunodeficiency (SCID) bearing solid human A431 xenograft tumours with SM/cholesterol vincristine formulations delayed the time required for 100% increase in tumour mass to > 40 days, compared with 5 days, 7 days and 14 days for mice receiving no treatment or treatment with free vincristine or DSPC/cholesterol formulations of vincristine respectively.
机译:这项研究报告了长春新碱脂质体制剂的开发,该制剂具有显着增强的稳定性和生物学特性。将基于鞘磷脂(SM)和胆固醇的脂质体长春新碱制剂的体外和体内药代动力学,肿瘤传递和功效特性与由硬脂酰磷脂酰胆碱(DSPC)和胆固醇组成的脂质体进行了比较。 SM /胆固醇脂质体的体外稳定性明显高于类似的DSPC /胆固醇脂质体。与DSPC /胆固醇相比,SM /胆固醇脂质体还具有显着改善的生物学特性。具体地说,静脉内施用的SM /胆固醇脂质体在循环72小时后保留了25%的被包裹长春新碱,而DSPC /胆固醇脂质体中保留了5%。 SM /胆固醇脂质体的保留性能提高,导致血浆长春新碱水平比DSPC /胆固醇脂质体高7倍。长春新碱在SM /胆固醇脂质体中循环寿命的改善与腹水小鼠P388肿瘤和皮下A431实体异种移植瘤中长春新碱积累的增加有关。长春新碱向肿瘤的递送增加还伴随着抗肿瘤功效的增加。用长春新碱的SM /胆固醇脂质体制剂治疗患有腹水性P388肿瘤的小鼠,治愈率超过50%,而DSPC /胆固醇制剂则无法实现这种活性。同样,使用SM /胆固醇长春新碱制剂治疗患有严重合并免疫缺陷症(SCID)的携带人A431实体异种移植瘤的小鼠,与5天,7天和14天相比,将肿瘤质量增加100%所需的时间延迟到40天以上分别用于未接受或接受游离长春新碱或长春新碱的DSPC /胆固醇制剂治疗的小鼠。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号